Abstract: p-Acyloxybenzene sulfonates, well suited for detergency applications, are facilely and rapidly prepared by acylating an alkali or alkaline earth metal, or ammonium p-phenol sulfonate, with an anhydride of a straight or branched chain carboxylic acid having from 7 to 12 carbon atoms, in a polar aprotic solvent and in the presence of a catalytically effective amount of an alkali or alkaline earth metal salt of a straight or branched chain aliphatic carboxylic acid having from 7 to 12 carbon atoms.

Abstract: A process for preparing alkali metal salts of trifluoroacetic acid in the anhydrous and crystalline state. In a first stage, trifluoroacetic acid is neutralized with an alkaline agent in a medium consisting essentially of an alcohol containing 3 to 4 carbon atoms. In a second stage, the water formed by the neutralization reaction is removed by azeotropic distillation. In a third state, the remainder not removed by distillation in the second stage is treated by adding a hydrocarbon which does not solubilize an alkali metal trifluoroacetate and which forms an azeotrope with the alcohol to separate crystals of anhydrous alkali metal trifluoroacetate.

Abstract: Novel compounds and compositions which inhibit SRS-A in mammals are disclosed. Methods for preparing said compounds and compositions and methods for their use for treating allergic reactions, inflammation and for reducing the severity of myocardial infarction resulting from heart attack are disclosed.Useful intermediates for preparing said compounds are also disclosed.

Abstract: Disclosed herein are dialkanoyloxybenzylidene dialkanoate represented by the formula, ##STR1## wherein X.sup.1 and X.sup.2 represent respectively alkanoyloxy group and a pharmaceutical composition in dosage unit form which comprises a dosage effective for the treatment of inflammatory disease of the dialkanoyloxybenzylidene dialkanoate as an active ingredient thereof.

Abstract: Disclosed herein is a process for producing 2,6-naphthalenedicarboxylic acid together with trimellitic acid comprising oxidizing 2,6-diisopropylnaphthalene with molecular oxygen in the presence of a catalyst comprising a heavy metal(s) and bromine.

Abstract: A process for the manufacture of polycarboxylic acids is disclosed. In this novel process, iron is used to improve the selectivity of cobalt-manganese-bromine or zirconium-cobalt-manganese-bromine oxidation system. Polycarboxylic acids such as pseudocumene are converted to trimellitic acid which is used to manufacture plasticizers and polyamide-imide polymers used as molding compounds for replacement of metals.

Abstract: Cyclohexane dicarboxylic acids are prepared by hydrogenating phthalic acids in presence of a rhodium catalyst wherein a portion of the product stream is isolated and recycled to the reactor.

Abstract: A process is described for the preparation of cis-5-fluoro-2-methyl-1-(4-methylthiobenzylidene)-indene-3-acetic acid that consists in reacting a lower alkyl ester of 5-fluoro-2-methylindene-3-acetic acid with a substantially equimolecular amount of 4-methylthio-benzaldehyde in a solid-liquid two-phase system in which the solid phase is a potassium alcoholate or hydroxide and the liquid phase is a solution of the reagents in an organic solvent inert in the reaction conditions, in the presence of a phase transfer catalyst and at a temperature comprised between -20.degree. and +20.degree. C.

Abstract: The present invention relates to compounds which are 4-hydroxy-4-alkenylcyclohexanecarboxylic acid derivatives possessing leukotriene antagonist activity. The compounds are useful in the treatment of allergic diseases, particularly in the treatment of human asthma. They are prepared by the reaction of an appropriate oxaspiro compound with a mercaptoalkanoic acid derivative.

Abstract: Process for the production of substituted 2-oxocyclohexaneacetic acid esters and intermediates used for their production. The substituted 2-oxocyclohexaneacetic acid esters are themselves useful intermediates for the manufacture of substituted 2,3,4,9-tetrahydro-1H-carbazole-1-acetic acid derivatives having useful analgesic and anti-inflammatory activity.

Abstract: A class of novel tertiary alkyl isocyanates. Of these, novel carbonate diisocyanates can be prepared by contacting a carbonyl dihalide and an aminotertiaryalkylhydroxyaromatic compound in the presence of a base and a reaction medium under reaction conditions.

Abstract: Substituted oxime-ethers of the formulae ##STR1## where R.sup.1 and R.sup.2 independently of one another are C.sub.1 -C.sub.6 -alkyl, n is 2 or 3 and R.sup.3 is hydrogen or C.sub.1 -C.sub.6 -alkyl.

Abstract: Compounds of the general formula I ##STR1## in which R is a hydrogen or halogen atom, a cyanide or an alkyl group having 1-4 carbon atoms andR.sub.1 is a hydrogen or halogen atom, nitro, alkyl, alkoxy, aryl, aryloxy, acyl or alkoxycarbonyl group,are prepared by esterifying two adjacent OH groups to give the cyclic carbonate, esterifying the free OH group with (meth)acrylic acid and selectively hydrolyzing the carbonate. The compounds are free of polyunsaturated impurities and can be used for preparing purely linear polymers.

Abstract: Novel chemical compounds are provided which selectively inhibit the metabolism of renal dipeptidase (E.C.3.4.13.11) and therefore are useful in combination with antibacterial products. These chemical compounds are (Z,Z)-.alpha.,.alpha.'-bis(2,2-disubstituted cyclopropanecarboxamido)-.alpha.,.alpha.'-alkadienedioic acids.

Abstract: Perfluoropolycycloalkanes are provided. These perfluoropolycycloalkanes are ring assemblies having (a) at least two perfluorinated cyclohexane rings, (b) at least two perfluorinated fused ring systems, or (c) combinations of at least one perfluorinated cyclohexane ring with at least one perfluorinated fused ring system, each perfluorinated ring or fused ring system being directly joined to another perfluorinated ring or ring system by a single bond and the ring assemblies having a total of at least 13 carbon atoms.

Abstract: Compounds useful in treating cardiovascular disorders such as thrombosis, hypertension and atherosclerosis are depicted in formulas (1), (2) and (3): ##STR1## wherein: A is --C.tbd.C--, trans --HC.dbd.CH--, --CH.sub.2 CH.sub.2 -- or --CH.dbd.CHCH.sub.2 --;X is lower alkoxy, hydroxy, or (2,2,2)-trifluoroethoxy;Y is hydrogen, exo-(lower alkyl) or endo-(lower alkyl);is an integer of 2-4;R.sub.1 is --CH.sub.2 OH, --CHO, --CO.sub.2 R or --CO.sub.2 H, and the olefin formed by the R.sub.1 (CH.sub.2).sub.n CH.dbd. moiety is either (E) or (Z);R.sub.2 is hydrogen or methyl, or optionally --CH.dbd.CH.sub.2 when A is --CH.dbd.CHCH.sub.2 --; andR.sub.3 is linear or branched alkyl, alkenyl or alkynyl having 5-10 carbon atoms, ##STR2## --(CH.sub.2).sub.m -phenyl or CH.sub.

Abstract: Process for preparing Naproxen via a sequence of stereospecific reactions which comprises: condensation of 1-chloro-2-methoxy-naphthalene with a (S)-2-halo-propionyl halide according to the Friedel-Crafts reaction, ketalization of the thus obtained (S)-2-halo-1-(5'-chloro-6'-methoxy-2'-naphthyl)-propan-1-one, rearrangement of said ketal to afford an ester, hydrolysis of the ester and removal of the chlorine atom in 5-position by hydrogenolysis.New (S) 2-halo-1-(5'-chloro-6'-methoxy-2'-naphthyl)-propan-1-ones.

Abstract: Disclosed herein are N-[[6-methoxy-5-(trifluoromethyl)-1-naphthalenyl]-thioxomethyl]-N-methylgl ycine S-oxide (tolrestat S-oxide) and the amide thereof and methods of their preparation. The S-oxides are new aldose reductase inhibitors useful for the treatment of prevention of diabetic complications.

Abstract: An improved process for the preparation of 3,5-dialkyl-4-hydroxybenzoic acid comprising the reaction of 2,6-dialkylphenol and carbon dioxide in the presence of a mono- or polyalkylene glycol ether.

Abstract: The present invention is related to new S-(Carbamoyl-phenylselenyl) derivatives of mercaptanes of the general formula (I) ##STR1## and to a process for the treatment of diseases caused by cell injury due to the increased formation of active oxygen metabolites.